Reed Jobs on biotech, AI, and why he doesn't lean on his last name

Reed Jobs's firm Yosemite Ventures has gone from a startup fund to a 17-person outfit in three years. The timing is good for biotech: a pile of blockbuster drugs is expiring patents at roughly the same time, opening a window for generics and biosimilars. Jobs says AI has become a big part of what they do — not as a gimmick, but as something they're actually using in the work.

He'd rather talk about curing cancer than his last name, and the track record backs that up. Yosemite's been backing companies in biotech and climate tech since it launched. The firm is now moving faster than Jobs expected, riding a sector that's still shaking off the post-pandemic crash while the next wave of deals lines up.

Why this matters for us: biotech and climate startups are where the real money is heading, and when the people writing checks don't feel the need to lean on a famous last name, that usually means they're betting on the work — and the work can open doors for founders who don't come from the right zip code.